Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1.

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-07-05 Print Date: 2017-07-01 DOI:10.1128/CVI.00068-17

Christina E Nixon, Sangshin Park, Sunthorn Pond-Tor, Dipak Raj, Lynn E Lambert, Sachy Orr-Gonzalez, Emma K Barnafo, Kelly M Rausch, Jennifer F Friedman, Michal Fried, Patrick E Duffy, Jonathan D Kurtis

{"title":"Identification of Protective B-Cell Epitopes within the Novel Malaria Vaccine Candidate Plasmodium falciparum Schizont Egress Antigen 1.","authors":"Christina E Nixon, Sangshin Park, Sunthorn Pond-Tor, Dipak Raj, Lynn E Lambert, Sachy Orr-Gonzalez, Emma K Barnafo, Kelly M Rausch, Jennifer F Friedman, Michal Fried, Patrick E Duffy, Jonathan D Kurtis","doi":"10.1128/CVI.00068-17","DOIUrl":null,"url":null,"abstract":"Naturally acquired antibodies to Plasmodium falciparum schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from Plasmodium berghei (PbSEA-1A) decreases parasitemia and prolongs survival following P. berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"24 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00068-17","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00068-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 11

Abstract

Naturally acquired antibodies to Plasmodium falciparum schizont egress antigen 1 (PfSEA-1A) are associated with protection against severe malaria in children. Vaccination of mice with SEA-1A from Plasmodium berghei (PbSEA-1A) decreases parasitemia and prolongs survival following P. berghei ANKA challenge. To enhance the immunogenicity of PfSEA-1A, we identified five linear B-cell epitopes using peptide microarrays probed with antisera from nonhuman primates vaccinated with recombinant PfSEA-1A (rPfSEA-1A). We evaluated the relationship between epitope-specific antibody levels and protection from parasitemia in a longitudinal treatment-reinfection cohort in western Kenya. Antibodies to three epitopes were associated with 16 to 17% decreased parasitemia over an 18-week high transmission season. We are currently designing immunogens to enhance antibody responses to these three epitopes.

Abstract Image

查看原文本刊更多论文

新型疟疾候选疫苗恶性疟原虫分裂体输出抗原保护性b细胞表位的鉴定

恶性疟原虫分裂体出口抗原1 (PfSEA-1A)的自然获得性抗体与儿童预防严重疟疾有关。接种柏氏疟原虫SEA-1A (PbSEA-1A)小鼠可减少寄生虫血症，延长柏氏疟原虫ANKA攻击后的存活时间。为了增强PfSEA-1A的免疫原性，我们利用接种了重组PfSEA-1A (rPfSEA-1A)的非人灵长类动物抗血清的肽微阵列探针鉴定了5个线性b细胞表位。我们在肯尼亚西部的纵向治疗-再感染队列中评估了表位特异性抗体水平与寄生虫病保护之间的关系。在18周的高传播季节中，针对三个表位的抗体与寄生虫率降低16%至17%相关。我们目前正在设计免疫原来增强对这三个表位的抗体反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.